Jeffrey Dunn, MD

Clinical Focus

• Multiple Sclerosis
• Neuromyelitis Optica
• Transverse Myelitis
• Neurology

Administrative Appointments

• Director, Neurology Clerkship Program (2009 - present)
• Associate Director, Stanford Multiple Sclerosis Center (2008 - present)
• Chair, National MS Society NorCal Chapter CAC (2008 - present)

Honors and Awards

• Excellence in Teaching Award, Stanford University School of Medicine (2009-2010)
• Lysia K. Forno Award for Excellence in Teaching Neurology Residents, Stanford University Department of Neurology & Neurosciences (2008-2009)
• Fellow, American Academy of Neurology (2008)
• "America's Top Rated Physicians", Guide to Top Doctors (1998-2007)

Professional Education

Graduate & Fellowship Program Affiliations

• Neurology and Neurol Sciences

Community & International Work

• PACTRIMS Member 

Web Site Links

• http://neurology.stanford.edu

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

Clinical translational research in the human application of emerging immunotherapies for neuroimmunologic diseases, including Multiple Sclerosis, CIS and Neuromyelitis Optica. Collaborative research with Stanford and extramural faculty to identify biomarkers of diesease activity and treatment response. Recent MS clinical trials include studies of alemtuzumab, oral sphingosine 1 phosphate inhibition, NIH CombiRx and Biomarkers, Subcutaneous Tovaxin in Subjects with CIS, Subcutaneous Daclizumab, NC-100 Novantrone induction, dose ranging GA pilot trial, natalizumab safety and tolerability monitoring and sub-investigation of FTY720, Fampridine SR, and RTL-1000 for secondary progressive MS.

Clinical Trials

• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two (CARE-MS II) No longer recruiting
• Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS) Not yet recruiting

Publications

• The Impact of Mobility Impairment on the burden of Caregiving in Multiple Sclerosis Dunn, J., American Journal of Pharmacy Benefits. 2009 submitted
• CMV Optic Neuritis with Extensive Tracking along the Visual Pathway Pershing S, Dunn J, Khan A, Liao JY, J Neuro-Ophthalmology. 2009; 29 (3): 223-226
• Fampridine: Mechanism of Action in the Targeted Treatment of Walking Impairment in Patients with Multiple Sclerosis Dunn, J, et al. in preparation. 2009
• Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS Fox, EJ, The TERMS Study Investigators. Multiple Sclerosis. 2008: 14 S5-S27
• Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS Arnold D., Campagnolo D., Panitch H., Bar-Or A., Dunn J, Freedman M., Gazda S.K., Vollmer T., J Neurol. 2008: 255 1473-1478